OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Prognostic impact of IL7R mutations on acute myeloid leukemia	26
Monocyte or white blood cell counts and β₂ microglobulin predict the durable efficacy of daratumumab with lenalidomide	26
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis	25
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges	25
Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-versus-host disease in pediatric patients with acquired severe ap	24
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study	23
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match	20
Total body irradiation-based myeloablative conditioning for acute lymphoblastic leukaemia patients undergoing allogeneic haematopoietic stem cell transplantation: the best way to prevent relapse in a	19
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine	19
Supporting leukemia patients in the Philippines: a call to action	18
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment	18
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff	18
Using T-lymphocyte subsets at engraftment to predict the risk of acute graft-versus-host disease in patients with thalassemia major: development of a new predictive nomogram	15
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series	14
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study	13
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies	13
Brain iron content and cognitive function in patients with β-thalassemia	12
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality	12
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report	12
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from	11
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers	11
The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study	11
Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia	11
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib	10
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)	10

A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient	9
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis	9
Down syndrome-associated leukaemias: current evidence and challenges	9
A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients	9
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors	9
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy	8
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia	8
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report	8
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments	8
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis	8
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia	8
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria	8
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma	8
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase	8
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia	8
Successful treatment of hemophagocytic intravascular large B-cell lymphoma with CNS involvement with BTK inhibitor combined with rituximab and high-dose methotrexate	7
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation	7
Intensive chemotherapy with dual induction and ALL-like consolidation for childhood acute myeloid leukemia: a respective report from multiple centers in China	7
Rapid and sustained response to luspatercept and eltrombopag combined treatment in one case of clonal cytopenias of undetermined significance with prior failure to cyclosporin and androgen therapy: a	7
Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy	6
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study	6
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group	6
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia	6
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia	6
Macrofocal multiple myeloma in the era of novel agents in China	6
Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses	6
Role of abatacept in the prevention of graft-versus-host disease: current perspectives	6
Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China	6
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?	5
Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review	5
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data	5
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study	5
Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study	5
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia	4
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente	4
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia	4
Treatment of multiple myeloma: What is the impact on T-cell function?	4
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study	4
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors	4
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry	4
Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens	4
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms	4
Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab	4
Current state of CAR-T therapy for T-cell malignancies	3
International consensus recommendations on the management of people with haemophilia B	3
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells	3
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma	3
Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report	3
Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients	3
Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms	3

Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature	3
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study	3
MYD88^L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy	2
Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States	2
High expression of malic enzyme 1 predicts adverse prognosis in patients with cytogenetically normal acute myeloid leukaemia and promotes leukaemogenesis through the IL-6/JAK2/STAT3 pathways	2
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase in	2
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study	2
Iron overload status in patients with non-transfusion-dependent thalassemia in China	2
The impact of granulocyte colony-stimulating factor and decitabine-containing conditioning in myelodysplastic syndrome patients with iron overload undergoing allogeneic hematopoietic stem cell transpl	2
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study	2
Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions	2
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review	2
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma	2
Experience in the management of patients with HTLV-1 positive adult T-cell leukemia/lymphoma in a Latin American center	2
Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS	2
Management of mycosis fungoides and Sézary syndrome with mogamulizumab in combination with psoralen plus UVA: two case reports	2
Luspatercept for transfusion-dependent β-thalassemia: time to get real	2
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy	2
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study	2
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)	2
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China	2
Simoctocog alfa (Nuwiq^®) in children: early steps in life’s journey for people with severe hemophilia A	2
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes	2
The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation	2
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma	2